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Abstract
Background Three EQ-5D value sets (EQ-5D-3L, cross-
walk, and EQ-5D-5L) are now available for cost-utility
analysis in the UK and/or England. The value sets’ char-
acteristics differ, and it is important to assess the impli-
cations of these differences.
Objective The aim of this paper is to compare the three
value sets.
Methods We carried out analysis comparing the predicted
values from each value set, and investigated how differ-
ences in health on the descriptive system is reflected in the
utility score by assessing the value of adjacent states. We
also assessed differences in values using data from patients
who completed both EQ-5D-3L and EQ-5D-5L.
Results The distribution of the value sets systematically
differed. EQ-5D-5L values were higher than EQ-5D-3L/
crosswalk values. The overall range and difference
between adjacent states was smaller. In the patient data, the
EQ-5D-5L produced higher values across all conditions
and there was some evidence that the value sets rank dif-
ferent health conditions in a similar severity order.
Conclusions There are important differences between the
value sets. Due to the smaller range of EQ-5D-5L values,
the possible change in quality-adjusted life years (QALYs)
might be reduced, but they will apply to both control and
intervention groups, and will depend on whether the gain is
in quality of life, survival, or both. The increased sensi-
tivity of EQ-5D-5L may also favour QALY gains even if
the changes in utility are smaller. Further work should
assess the impact of the different value sets on cost
effectiveness by repeating the analysis on clinical trial data.
Key Points for Decision Makers
There are differences between the UK EQ-5D-3L
and English EQ-5D-5L value sets.
The choice of value set will have implications for the
decision-making process carried out by the National
Institute of Health and Care Excellence.
1 Introduction
In the economic evaluation of of health interventions, the
quality-adjusted life year (QALY) is a commonly used
metric that combines length and quality of life into a single
figure. The quality, or utility, weight used in the estimation
of QALYs is anchored on a full health (1) to dead (0) scale,
with negative values assigned to health states considered
worse than dead. Utility values for health states associated
with a particular condition or disease can be derived in
The original version of this article was revised due to a retrospective
Open Access order.
& Brendan Mulhern
Brendan.mulhern@chere.uts.edu.au
1 Centre for Health Economics Research and Evaluation,
University of Technology Sydney, 1-59 Quay St, Haymarket,
Sydney, NSW 2000, Australia
2 Office of Health Economics, Southside, 105 Victoria Street,
London SW1E 6QT, UK
3 Department of Medical Psychology and Psychotherapy,
Erasmus MC, Erasmus University, PO Box 2040, 3000 CA
Rotterdam, The Netherlands
4 Health Economics and Decision Science, School of Health
and Related Research, University of Sheffield, Regent Court,
30 Regent St, Sheffield S1 4DA, UK
PharmacoEconomics (2018) 36:699–713
https://doi.org/10.1007/s40273-018-0628-3
several ways, one of which is via the use of preference-
based measures (PBMs) of health. Of currently available
PBMs, the EQ-5D [1, 2] is the most widely used.
EQ-5D classifies health on five dimensions: mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression. The original version of the EQ-5D (described
as EQ-5D-3L) included three severity levels (none, some,
extreme/unable to)1, thereby describing (35 =) 243 health
states. In the UK, utility values for EQ-5D-3L health states
were derived using the time trade-off (TTO) preference
elicitation technique [3]. The resulting ‘value set’ has been
widely influential, and is preferred by the National Institute
for Health and Care Excellence (NICE) for use in the cost-
utility analysis of health interventions [4]. EQ-5D-3L val-
ues are also accepted by reimbursement agencies world-
wide, including the Pharmaceutical Benefits Advisory
Committee (PBAC) in Australia [5] and the Canadian
Agency for Drugs and Technology in Health (CADTH) in
Canada [6]. The instrument itself is also used in a wide
range of settings, including population health surveys and
routine clinical practice [7].
Notwithstanding the widespread use of the EQ-5D-3L
descriptive system and value set, research has suggested
that both have a number of limitations. Regarding the
descriptive system, it has been shown that the EQ-5D-3L is
not sensitive to the important quality of life impacts of all
conditions [8, 9]. It may also not be sensitive to smaller
changes in health as it only has three response levels in
each dimension, and in general public and some patient
samples, a substantial proportion of respondents report
themselves as being in the best health state, i.e. no prob-
lems on any dimension (11111). This is known as a ceiling
effect [10]. Regarding the value set, the procedure and
modelling used to elicit values for worse than dead health
states has been criticised [11]. Furthermore, the EQ-5D-3L
valuation data were collected in 1993, and population
preferences for different aspects of health and quality of
life may have changed in this time given advances in
treatment and care. Social and environmental changes may
also be important.
In an effort to improve the instrument’s sensitivity and
reduce the ceiling effect, a five-level descriptive system,
the EQ-5D-5L [12], was developed. The new instrument
includes five response levels (none, slight, moderate, sev-
ere, extreme/unable to). The wording was also standardised
across dimensions so that the worst level of mobility was
changed from ‘confined to bed’ to ‘unable to walk about’,
which is in line with the severity indicators used for the
other functioning dimensions (self-care and usual activi-
ties). The intermediate severity level was also standardised
to be ‘moderate’. The EQ-5D-5L increases the number of
states described to (55 =) 3125. Research has shown
improved measurement properties of the EQ-5D-5L
descriptive system across a number of patient samples
when compared to the EQ-5D-3L [13].
One consequence of this initiative was the need to
develop value sets for the new descriptive system that
reflect more up-to-date preferences of the population for
health and quality of life, and this resulted in two separate
developments. Firstly, an interim ‘crosswalk’ value set was
developed so that EQ-5D-3L values could be used to pre-
dict EQ-5D-5L values [14]. Secondly, in order to elicit
values for health states generated by the EQ-5D-5L
descriptive system, a new valuation protocol combining
TTO and discrete choice experiment (DCE) methods was
developed [15]. This protocol used a ‘composite’ TTO
approach combining standard and ‘lead time’ TTO
[15–17]. In England, health states generated by the EQ-5D-
5L were valued during 2012 and 2013 using this protocol
and subsequently modelled using newly developed tech-
niques that combined TTO and DCE data in a hybrid model
to produce an EQ-5D-5L value set [18, 19].
Three EQ-5D value sets are therefore now available for
use in cost-utility analysis in the UK and/or England, those
being the EQ-5D-3L value set, the crosswalk value set
mapping the EQ-5D-5L descriptive system onto the EQ-
5D-3L value set, and the EQ-5D-5L value set. The first two
of these were developed based on valuations from
respondents in the UK, while the latter was based on val-
uations from respondents in England only. However, this is
only one way in which they differ. As noted, they are also
based on different descriptive systems, valuation protocols,
and modelling methods. Given widespread and increasing
use of the EQ-5D-5L in decision making, it is important to
systematically assess the differences between the value
sets, and the implications of the new values. For example,
in recent work, it has been found that quality of life
changes are valued less using the EQ-5D-5L value set [20].
At the end of 2017, NICE released a position statement
regarding the use of the EQ-5D-5L stating that ‘‘the map-
ping function developed by van Hout et al. [14] [i.e. the
crosswalk value set] should be used for reference-case
analyses’’ until its position is reviewed in 2018 [21]. This
means that the UK crosswalk is currently important in
health technology assessment (HTA) carried out by NICE,
and the results of studies comparing the new EQ-5D-5L
value set with the crosswalk and EQ-5D-3L will inform
future decisions about which measure to use. Therefore the
aim of this paper is to add to the literature in this area by
comparing the UK EQ-5D-3L and English EQ-5D-5L
value sets, and the EQ-5D-5L and crosswalk value sets.
1 In the EQ-5D-3L, level 3 mobility was described as ‘confined to
bed’ not ‘unable to’.
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2 Methods
2.1 The Value Sets
In the sections below, EQ-5D health states are described
using five digits corresponding to each dimension and each
level. The dimensions are listed in the order presented on
the questionnaire (mobility, self-care, usual activities, pain/
discomfort, anxiety/depression). For the EQ-5D-3L, 1
represents no problems, 2 some problems, and 3 extreme
problems/confined to bed. Therefore EQ-5D-3L state
22222 describes some problems on each of the five
dimensions. For the EQ-5D-5L, 1 represents no problems,
2 slight problems, 3 moderate problems, 4 severe problems,
and 5 extreme problems/unable to. Therefore EQ-5D-5L
state 22222 describes slight problems on each dimension.
2.1.1 EQ-5D-3L
The UK EQ-5D-3L value set [3] was developed using data
collected in 1993 from 2997 general population respon-
dents who were sampled from the Postcode Address File.
Respondents were recruited to be representative of the non-
institutionalised adult population of England, Scotland, and
Wales, and had similar characteristics to the UK General
Health Survey sample [3]. Each respondent completed a
face-to-face interview and valued 13 states (12 EQ-5D-3L
profiles plus ‘unconscious’) using TTO which included one
procedure for states valued better than dead and a different
process for states valued worse than dead. In total, 42 of the
243 EQ-5D-3L states were valued, with an overrepresen-
tation of the mildest health states. The data were modelled
using additive generalised least squares (GLS) regression
to produce a value set ranging from 1 (for the best state,
11111) to - 0.594 (for the worst state, 33333), with 34.6%
of states valued as worse than dead. The model includes a
constant subtracted for any move away from full health, a
further decrement for each move away from ‘no problems’
for each dimension, and an additional term that is sub-
tracted if any dimension is at the worst level (known as the
‘N3 term’). The value set also has a large change in utility
between 11111 and the next best state (11211, which is
scored at 0.883).
2.1.2 Crosswalk
Crosswalk value sets were developed by van Hout et al.
[14] from a multicountry study of respondents who com-
pleted both the EQ-5D-3L and EQ-5D-5L in 2010. The
crosswalk used a non-parametric response mapping method
to predict values that are linked to the EQ-5D-3L value set.
The decrements for the ‘equivalent’ levels of the two
descriptive systems are the same. This means that the
decrements for level 3 of the EQ-5D-5L (moderate prob-
lems) are the same as level 2 of the EQ-5D-3L (some
problems), and those for level 5 of the EQ-5D-5L are the
same as level 3 of the EQ-5D-3L. This means that the
range of values is the same (55555 on the EQ-5D-5L has
the same value as 33333 on the EQ-5D-3L, and an example
intermediate state 35353 on the EQ-5D-5L has the same
value as 23232 on the EQ-5D-3L). The crosswalk can link
EQ-5D-5L data to a range of existing international EQ-5D-
3L value sets. For the purposes of this paper, we focus on
the crosswalk to the UK value set.
2.1.3 EQ-5D-5L
The English EQ-5D-5L value set [18] was developed from
996 members of the general population who were purpo-
sively sampled from the Postcode Address File. In contrast
to the EQ-5D-3L, respondents representative of the popu-
lation of England (as opposed to the wider UK; a UK value
set reflecting the preferences of respondents in England,
Scotland, Wales, and Northern Ireland is due to follow)
were recruited. The sample used differed slightly to the
actual population as there were more older and retired
people. Preferences were elicited using computer-assisted
face-to-face valuation interviews that were conducted in
2012 and 2013. Respondents valued ten EQ-5D-5L states
using composite TTO [15, 16] and completed seven DCE
paired comparison tasks. In total, 86 states were valued in
the TTO exercise and 196 pairs in the DCE tasks. The data
was modelled using heterogeneous hybrid approaches
combining the TTO and DCE data [19]. The resulting tariff
ranges from 1 to - 0.285, with 5.1% of the states valued as
worse than dead. The model includes a decrement for each
dimension for each move away from full health, and an
extra ‘scalar’ coefficient. The range of values is therefore
smaller than for the EQ-5D-3L, despite the considerable
increase in the number of possible health states. The value
of the mildest health states other than 11111 (12111 and
11211) is 0.950.
2.2 Analysis
We carried out an analysis comparing the predicted values
from each of the three value sets, and also using patient
reported EQ-5D-3L and EQ-5D-5L data. The patient data
were taken from the crosswalk development study dataset
where all respondents self-reported their health using both
the EQ-5D-3L and EQ-5D-5L descriptive systems, thereby
enabling direct comparisons. The key comparisons carried
out were between the EQ-5D-3L and EQ-5D-5L value sets,
and the EQ-5D-5L value set and the crosswalk tariff.
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2.3 Comparison of Predicted Values
2.3.1 Comparing Value Set Models
Firstly we compared the coefficient models used to calcu-
late the values. This was done to assess the overall mag-
nitude of the coefficients for each dimension, and the
impact of the various interaction coefficients included in
each model on the values produced. We also compared the
process for calculating values using an example health
state.
2.3.2 Comparing Value Set Characteristics
We assessed a range of descriptive statistics of the possible
theoretical values (i.e. 243 for the EQ-5D-3L and 3125 for
the EQ-5D-5L). This included the value set range, the
percentage of states valued as worse than dead, and the
state with the smallest utility decrement from 11111. We
looked at the modality of the overall distributions using
kernel density histograms, and compared the values of
selected states to demonstrate differences between the
value sets.
2.3.3 Comparing Value Set Characteristics for Matched
States
We carried out a comparative analysis on the states that are
comparable across the EQ-5D-3L and EQ-5D-5L (i.e. the
matched 243 states). The crosswalk value set is not rele-
vant here, as for these states, the values are the same as the
EQ-5D-3L tariff due to the response mapping procedure
used. We considered comparable states to be those from
the intermediate levels of the EQ-5D-5L descriptive system
(i.e. none, moderate, and extreme/unable to) which, to a
certain extent, ‘match’ the three-level states (as an exam-
ple, the EQ-5D-3L state 12321 is defined as comparable to
13531 on the EQ-5D-5L). We assessed similarities and
differences, both for individual states and at the overall
level, to highlight where the largest differences occur
across the value sets.
2.3.4 Comparing Differences in Utility Between Adjacent
States
Analysis was also carried out to understand how changes in
severity on the descriptive system are reflected by changes
in utility. This was done by assessing the values of adjacent
states within the descriptive system, and comparing the
differences across the three value sets. An adjacent state
pair was defined as having one dimension with a one-level
difference (for example, calculating the change in utility
between 21111 and 11111). This was done for states where
only one dimension changed at a time, so we focused on
the change in utility between level 3/5 and level 1 on one
dimension, with the other four dimensions held at the same
level. For example, for mobility, we compared the increase
in utility between 51111, 41111, 31111, 21111, and 11111,
and we repeated this for all five dimensions. The magni-
tude of the change between all level changes, and the
matched states, was assessed. This analysis reflects the
coefficient decrements in a different way and provides an
insight about how change in self-reported health would
lead to change in utility in the absence of longitudinal data.
2.4 Analysis on Patient Data
2.4.1 Data Used
The data used to develop the crosswalk value sets were
used for the analysis. The data were collected online across
a range of patient groups with different health conditions
who completed both the EQ-5D-3L and EQ-5D-5L
descriptive systems. More information about the data col-
lection procedure is provided in van Hout et al. [14].
Respondents from seven countries took part, but the anal-
ysis reported here used only the English and Scottish data.
The characteristics of the 1501 respondents included are
reported in Table 1.
2.4.2 Comparing the Descriptive System and Value Sets
Firstly, we compared the number of respondents reporting
each level of the two descriptive systems. This was done to
understand how the addition of the two extra levels chan-
ges response patterns. We compared the values using
density plots, and also by assessing the scores overall and
across patient groups (with the exception of those with a
sample size of less than 50) using one-way ANOVA and
mean difference statistics. We also compared the agree-
ment between the value sets using Bland–Altman plots
[22]. These present the mean of two scores on the x-axis
and the difference on the y-axis, with lines indicating the
upper and lower limits of agreement [calculated as the
mean difference± 1.96 9 standard deviation (SD)] added.
Agreement across the full severity range can then be
assessed, with points outside the limits indicative of
outliers.
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3 Results
3.1 Comparison of Predicted Values
3.1.1 Comparing Value Set Models
The models used to derive EQ-5D-3L and EQ-5D-5L
values are displayed in Table 2. In each case, the coeffi-
cient decrements are larger for the more severe levels of
each dimension and are therefore ordered as expected. Both
models include a constant term, and in the EQ-5D-3L, this
involves a decrement of 0.081 for the move away from the
best health state (11111). The EQ-5D-5L constant is 1, and
the coefficients are the mean coefficients from the mod-
elling process after the application of the latent class
adjustments. The magnitude of the dimension level coef-
ficients between the EQ-5D-3L and EQ-5D-5L varies (for
example, pain/discomfort has a larger overall decrement on
the EQ-5D-3L and anxiety/depression has a larger decre-
ment on the EQ-5D-5L). The EQ-5D-3L N3 term is an
extra decrement when at least one of the levels is at the
most severe (i.e. level 3), and therefore this reduces the
value of the more severe states. Table 2 also displays how
to calculate a value for a state. The calculation is for the
value for EQ-5D-5L state 21223 and the equivalent EQ-
5D-5L state 31335, and this shows that the EQ-5D-3L
value is substantially lower (0.186 vs 0.488).
3.1.2 Comparing Value Set Characteristics
Table 3 (adapted from Devlin et al. [18]) compares the
descriptive characteristics of the three value sets. The EQ-
5D-5L value set has a higher value for the worst health
state and substantially fewer worse than dead values. Also,
the decrement from the best (11111) to next best health
state (11211) is smaller for the EQ-5D-5L value set. This is
expected given differences in labelling (e.g. 11211
describes ‘slight’ problems performing usual activities in
the five-level instrument and ‘some’ problems in the three-
level version). In all three value sets, pain/discomfort has
the largest overall decrement (but not at the less severe
levels), while self-care and usual activities have the
smallest.
Figure 1 compares all unique theoretical values for the
three value sets. The results demonstrate that the range for
the EQ-5D-3L and crosswalk is different from the EQ-5D-
5L. The large coefficients for level 3 on the EQ-5D-3L
(and the impact of the N3 term) means that there is a higher
density of lower values. The EQ-5D-5L is unimodal,
whereas the EQ-5D-3L has multiple clusters, as has pre-
viously been observed [23].
3.1.3 Comparing Value Set Characteristics for Matched
States
Figure 2 displays the values of the comparable states from
the EQ-5D-3L and the EQ-5D-5L value sets ordered by
descending EQ-5D-5L value. EQ-5D-3L values are con-
sistently lower across the full severity range. Figure 3
shows a histogram of the differences for each comparable
state across the value sets, and a box plot of the mean
difference by utility score category as a proxy for severity
(1 to 0.500; 0.499 to 0.200; 0.199 to 0; \0). The mean
difference is large overall at 0.312 (SD 0.102; range
0–0.484), and significantly increases as severity increases
(F3,239 = 196.0, p\0.001). Only 16 (6.6%) of 243 states
have a mean difference smaller than 0.1, and 40 (16.5%) of
the states have a difference of at least 0.4. The state with
Table 1 Demographic characteristics of the crosswalk data used for
the comparative analysis
Demographic N (%)
N 1501
Country
Scotland 500
England 1001
Age
Mean (SD) 57 (16)
Range 19–94
Gender male 734 (49)
Education
Left school with no qualifications 485 (32)
Left school with some qualifications 339 (23)
College degree/further education 377 (25)
Degree/postgraduate/professional 300 (20)
EQ-5D visual analogue scale
Mean (SD) 60.3 (21.4)
Range 0–100
Condition
COPD 320 (21)
Heart problems 251 (17)
Arthritis 250 (17)
Depression 250 (17)
Rheumatoid arthritis 87 (6)
Stroke 85 (6)
Back pain 70 (5)
ADHD 69 (5)
Diabetes 45 (3)
Parkinson’s 37 (3)
Breathing problems 22 (2)
Multiple sclerosis 15 (1)
ADHD attention deficit hyperactivity disorder, COPD chronic
obstructive pulmonary disease, SD standard deviation
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the largest difference is 32131 (53151 on EQ-5D-5L)
(0.484), and the state with the smallest difference (ex-
cluding the best state) is 11212 (11313 on EQ-5D-5L)
(0.023).
3.1.4 Comparing Differences in Utility Between Adjacent
States
Table 4 displays the change in utility between adjacent and
matched states. Comparisons of the matched states
demonstrate that the change in adjacent states is substan-
tially larger for the three-level tariff across all five
Table 2 Comparing the EQ-5D-3L and EQ-5D-5L models
Parameters EQ-5D-
3L
EQ-5D-
5La
Value calculation (21223/31335)
EQ-5D-3L EQ-5D-5L
Constant 0.081
EQ-5D dimensions
Mobility
None 0 0
Slight 0.058
Some/moderate 0.069 0.076 0.069 0.076
Severe 0.207
CTB/unable to 0.314 0.274
Self-care
None 0 0 0 0
Slight 0.050
Some/moderate 0.104 0.080
Severe 0.164
Unable to 0.214 0.203
Usual activities
None 0 0
Slight 0.050
Some/moderate 0.036 0.063 0.036 0.063
Severe 0.162
Unable to 0.094 0.184
Pain/discomfort
None 0 0
Slight 0.063
Some/moderate 0.123 0.084 0.123 0.084
Severe 0.276
Extreme 0.386 0.335
Anxiety/depression
None 0 0
Slight 0.078
Some/moderate 0.071 0.104
Severe 0.285
Extreme 0.236 0.289 0.236 0.289
Interactions
N3 term 0.269 0.269
Value of state 1- 0.081- 0.069- 0- 0.036- 0.123- 0.236-
0.269 = 0.186
1-
(0.076? 0? 0.063? 0.084? 0.289) = 0.488
CTB confined to bed
aMean coefficient from the Bayesian regression with the latent class adjustment applied
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dimensions. This may suggest that the use of the EQ-5D-
3L value set would tend to result in larger QALY gains for
purely quality of life-improving interventions. Regarding
EQ-5D-5L, the largest change in value occurs in the move
from severe (level 4) to moderate (level 3) reported health
problems. In contrast, the largest change in the crosswalk
value set is between extreme/unable to (5) and severe (4)
which is comparatively small in the EQ-5D-5L value set.
The change in the crosswalk values from slight (2) to no
problems (1) is larger than for EQ-5D-5L. This means that
interventions resulting in an improvement in both mild and
more severe health may result in larger QALY gains if the
crosswalk values were used.
3.2 Comparisons Using Patient Data
3.2.1 Comparing the Descriptive System and Value Sets
Table 5 displays the dimension level responses to the EQ-
5D-3L and EQ-5D-5L and shows that the largest impact of
the addition of the two intermediate levels (slight and
severe) is to spread the ‘some’ responses on the EQ-5D-3L
between levels 2–4 on the EQ-5D-5L. The introduction of
‘slight’ modestly reduces the ceiling effect as respondents
move away from reporting no problems given the increased
sensitivity. There is clear dispersion of scores from ‘some’
on the EQ-5D-3L across ‘slight’, ‘moderate’, and ‘severe’
on the EQ-5D-5L.
Table 3 Overall descriptive characteristics of the three value sets (modelled values)
EQ-5D-3L value set EQ-5D-5L crosswalk EQ-5D-5L value set
Range 1 to - 0.594 1 to - 0.594 1 to - 0.285
% health states worse than dead 34.6% 26.7% 5.1%
Dimension importance ordera Pain/discomfort
Mobility
Anxiety/depression
Self-care
Usual activities
Pain/discomfort
Mobility
Anxiety/depression
Self-care
Usual activities
Pain/discomfort
Anxiety/depression
Mobility
Self-care
Usual activities
Health state values
‘Mildest’ state (11211) 0.883 0.906 0.950 (11211/12111)
‘Moderate’ state [22222 (3L) or 33333 (5L)] 0.516 0.516 0.593
‘Worst’ state [33333 (3L) or 55555 (5L)] - 0.594 - 0.594 - 0.285
aImportance is judged by the size of the coefficient for level 5 in each dimension
0
.5
1
1.
5
2
D
en
si
ty
-.5 0 .5 1
Utility value
EQ-5D-5L EQ-5D-3L
Crosswalk
Fig. 1 All unique theoretical
values
Comparing EQ-5D Value Sets 705
Figure 4 compares the EQ-5D-3L, EQ-5D-5L, and EQ-
5D-5L crosswalk values. For the EQ-5D-3L, there is not
only a large decrease in values in the very mild area (due to
the upper gap reflected by the large constant), but also in
the moderate area around the values 0.25–0.45. In contrast,
the EQ-5D-5L has a smoother distribution. This reflects a
benefit of EQ-5D-5L: the increased sensitivity results in a
much smoother transition between adjacent values that are
Fig. 2 Values of comparable
states ordered by EQ-5D-5L
value
Fig. 3 Histogram and box plot of differences between the EQ-5D-3L and EQ-5D-5L value sets
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closer together than on the EQ-5D-3L. The crosswalk value
set distribution is more similar to the EQ-5D-5L, and the
lack of EQ-5D-3L values in the range between approxi-
mately 0.25 and 0.45 is not apparent.
Figure 5 compares the EQ-5D-3L and crosswalk with
the EQ-5D-5L and shows that there are differences in
values across the entire severity scale, but greater variation
for more severe health states (where the mean utility value
is lower for the EQ-5D-3L and crosswalk). Figure 6 dis-
plays Bland–Altman plots comparing EQ-5D-3L and EQ-
5D-5L, and EQ-5D-5L and crosswalk scores. There is
evidence of disagreement between values across the
severity scale, where the difference is outside the± 2 SD
range. Disagreement means more diverse utility scores for
states of a similar severity.
The mean difference between the EQ-5D-3L and EQ-
5D-5L values as reported by the patient sample is 0.073
(range - 0.944 to 0.880 calculated as EQ-5D-5L minus
EQ-5D-3L). Some respondents gave apparent inconsistent
responses, and this results in the wide range overall. For
example, the difference of - 0.944 results from a patient
reporting 21111 on EQ-5D-3L and 44444 on EQ-5D-5L.
Comparing the EQ-5D-5L and crosswalk value sets, the
mean absolute difference is 0.085 and ranges from 0.002
for the states with the smallest non-zero difference (44431,
42433, 43441, and 41231) to 0.429 (for state 51131).
Table 6 compares the value set scores overall and across
the different health conditions, with significance statistics
reported for the conditions with more than 50 patients. As
would be expected, the EQ-5D-5L values are higher, and
the difference is significant for the four conditions with the
largest sample size [chronic obstructive pulmonary disease
(COPD), heart problems, arthritis, and depression]. Of the
four conditions with a sample size of between 50 and 100,
the difference tends towards significance for stroke and
back pain, but not for attention deficit hyperactivity
Table 4 Comparing the change in utility between adjacent health states
EQ-5D-5L state EQ-5D-5L value set Crosswalk value set EQ-5D-3L state EQ-5D-3L value
set
Value Difference Difference matcheda Value Difference Difference matched Value Difference
11111 1.000 1.000 11111 1.000
21111 0.942 0.058 0.877 0.123
31111 0.924 0.018 0.076 0.850 0.027 0.150 21111 0.850 0.150
41111 0.793 0.131 0.813 0.037
51111 0.726 0.067 0.198 0.336 0.477 0.514 31111 0.336 0.514
11111 1.000 1.000 11111 1.000
12111 0.950 0.050 0.846 0.154
13111 0.920 0.030 0.080 0.815 0.031 0.185 12111 0.815 0.185
14111 0.836 0.084 0.723 0.092
15111 0.797 0.039 0.123 0.436 0.287 0.379 13111 0.436 0.379
11111 1.000 1.000 11111 1.000
11211 0.950 0.050 0.906 0.094
11311 0.937 0.013 0.063 0.883 0.023 0.117 11211 0.883 0.117
11411 0.838 0.099 0.776 0.107
11511 0.816 0.022 0.121 0.556 0.220 0.327 11311 0.556 0.327
11111 1.000 1.000 11111 1.000
11121 0.937 0.063 0.837 0.163
11131 0.916 0.021 0.084 0.796 0.041 0.204 11121 0.796 0.204
11141 0.724 0.192 0.584 0.212
11151 0.665 0.059 0.251 0.264 0.320 0.532 11131 0.264 0.532
11111 1.000 1.000 11111 1.000
11112 0.922 0.078 0.879 0.121
11113 0.896 0.026 0.104 0.848 0.031 0.152 11112 0.848 0.152
11114 0.715 0.181 0.635 0.213
11115 0.711 0.004 0.185 0.414 0.221 0.434 11113 0.414 0.434
aThe ‘difference matched’ calculation refers to the difference between states that are matched across the EQ-5D-3L and EQ-5D-5L (e.g. 31111
on the EQ-5D-5L is equivalent to 21111 on the EQ-5D-3L)
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disorder (ADHD) or rheumatoid arthritis. The percentage
of states worse than dead overall and also across each
condition is lower for the EQ-5D-5L. Table 6 also displays
the rank order of the severity of the conditions according to
the mean utility values. There is evidence of consistency
for seven of the 12 conditions, including the most
(Parkinson’s disease) and third most (back pain) severe
conditions, and the five least severe (ADHD, breathing
problems, arthritis, depression, and diabetes). The most
variable condition is multiple sclerosis, which is second
most severe according to the EQ-5D-3L, but fifth and sixth
equal overall according to the crosswalk and EQ-5D-5L
value sets, respectively.
4 Discussion
We have compared three EQ-5D value sets that can be used
to support HTA in the UK. The comparison firstly inves-
tigated differences in the ‘theoretical’ values possible from
the value sets for health states matched across the EQ-5D-
3L and EQ-5D-5L descriptive systems and secondly
compared values observed in patient data.
Regarding the theoretical values, the results demonstrate
that there are differences between the EQ-5D-3L and EQ-
5D-5L value sets, where the EQ-5D-5L values for matched
states are higher, and the overall range and therefore
change between adjacent states is smaller than for the EQ-
5D-3L. The distribution of values also differs. There are
similar differences between the EQ-5D-5L value set and
the crosswalk tariff given that the latter is linked to the EQ-
5D-3L value set. However, it is also worth noting that some
underlying features of the preferences, and therefore utility
scales, are similar. For example, the overall importance of
each dimension to the overall value is similar, with only
one difference (where the rank order of the dimensions is
the same, apart from two dimensions, mobility and anxiety/
depression, changing position in the ordering in the EQ-
5D-5L value set), and the relative distance between the
levels for different dimensions is similar.
Regarding the observed values from the patient data, the
EQ-5D-5L value set produces higher values overall and
across all of the conditions included, and the differences
are generally significant. This is expected given the overall
increase in the values of matched states and reduction in
the overall utility scale. There is some evidence that the
value sets rank different health conditions in a similar
order, particularly the most and least severe conditions as
measured by the descriptive systems. However, this
requires further exploration across a larger range of
conditions.
There are a number of possible reasons why the EQ-5D-
3L and EQ-5D-5L value sets differ. These include differ-
ences in the samples used in terms of demographics and
country. The EQ-5D-3L value set was based on a repre-
sentative sample of England, Scotland, and Wales, whereas
the EQ_5D-5L was based on just an English sample. This
may have implications for decision making in the juris-
dictions that are not represented. However, the project team
has since collected EQ-5D-5L valuation data for the other
countries in the UK so will be able to compare using a
more representative sample (albeit one that is smaller than
that used for the EQ-5D-3L). Potential changes in popu-
lation demographics and preferences over time (from 1993
to 2013) are another possible reason why the value sets
demonstrate differences. For example, the population is
getting older [24], and this might impact on preferences for
Table 5 Dimension level responses across the EQ-5D-3L/EQ-5D-5L
(English and Scottish data)
Dimension responses EQ-5D-3L, n (%) EQ-5D-5L, n (%)
Mobility
None 506 (33.7) 435 (29.0)
Slight 392 (26.1)
Some/moderate 983 (65.5) 377 (25.1)
Severe 277 (18.5)
CTB/unable to 12 (0.8) 20 (1.3)
Self-care
None 951 (63.4) 907 (60.4)
Slight 301 (20.1)
Some/moderate 517 (34.4) 201 (13.4)
Severe 74 (4.9)
Unable to 33 (2.2) 18 (1.2)
Usual activities
None 464 (30.9) 390 (26.0)
Slight 447 (29.8)
Some/moderate 881 (58.7) 358 (23.9)
Severe 228 (15.2)
Unable to 156 (10.4) 78 (5.2)
Pain/discomfort
None 380 (25.3) 303 (20.2)
Slight 447 (29.8)
Some/moderate 947 (63.1) 449 (29.9)
Severe 243 (16.2)
Extreme 174 (11.6) 59 (3.9)
Anxiety/depression
None 672 (44.8) 571 (38.0)
Slight 444 (29.6)
Some/moderate 721 (48.0) 324 (21.6)
Severe 111 (7.4)
Extreme 108 (7.2) 51 (3.4)
CTB confined to bed (level 3 of the EQ-5D-3L mobility dimension)
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different health dimensions. One indication of change in
preferences over time might be the increased magnitude of
the anxiety/depression dimension given increased focus on
the detrimental aspects of mental health conditions in
policy [25] and reduction in stigma surrounding conditions
such as depression [26]. Even without the development of
the EQ-5D-5L, the currently used EQ-5D-3L value set is
outdated and therefore would require updating anyway.
Overall, the dimension preference structure between the
EQ-5D-3L and EQ-5D-5L is similar, with only one
inversion (anxiety/depression and mobility), which is
encouraging given the differences between the studies.
This may demonstrate that the order of preferences for the
five areas of health described by the EQ-5D may be gen-
erally consistent over time.
Other reasons why the value sets may differ relate to the
descriptive system and the valuation method used. Firstly,
regarding the descriptive system, the EQ-5D-5L uses more
0
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5
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en
si
ty
-.6 -.4 -.2 0 .2 .4 .6 .8 1
EQ-5D values
EQ-5D-3L EQ-5D-5L
Crosswalk
Fig. 4 Comparison of all EQ-
5D-3L,EQ-5D-5L and EQ-5D-
5L crosswalk values
Fig. 5 EQ-5D-3L and crosswalk patient values ordered by EQ-5D-5L
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consistent wording, particularly for the more severe levels,
and it is possible that the change in labelling of the
mobility dimension (from ‘confined to bed’ to ‘unable to
walk about’) has impacted the values, where mobility has a
smaller weighting in the EQ-5D-5L than in the EQ-5D-3L.
The increase in levels and associated sensitivity also may
impact the magnitude of the difference and transition
between the intermediate levels and therefore the overall
value set.
Secondly, the valuation method differs, particularly
regarding the process used to value states worse than dead,
which was problematic for the EQ-5D-3L [11]. The
methodological change to a new approach to eliciting
values\0, the lead time TTO, meant that the lowest pos-
sible value for an EQ-5D-5L health state in the protocol
used was - 1 [15, 27]. In contrast, the minimum value was
- 39 in the Dolan study [3], which was rescaled to - 1.
This therefore led to a reduction in the overall scale. The
inclusion of DCE tasks in the EQ-5D-5L valuation also
provides a different type of valuation data focusing on the
choices between states rather than measuring direct values
for states, as is the case with TTO. The development of
innovative modelling methods combining TTO and DCE
data in one model [28, 29] provides further reasons for
differences in the value sets. The modelling process for the
EQ-5D-5L data also developed heterogeneous models for
the TTO data only [19], and further work is underway to
model the EQ-5D-3L valuation data applying the methods
developed for the EQ-5D-5L [30]. It is also worth noting
that a partial replication of the original EQ-5D-3L valua-
tion study was carried out by Macran and Kind [31]. In this
study, the authors used a smaller health state design, but a
similar TTO process to Dolan [3] and estimated an EQ-5D-
3L value set with quite different characteristics. For
example, the value for the worst state was substantially
higher (- 0.126 vs - 0.594), and the amount of negative
states was substantially lower (12.3 vs 34.6%). This value
set is more in line with other EQ-5D-3L value sets devel-
oped internationally [32], and provides a useful counter-
point for comparisons between the value sets included in
this study.
There are also large differences in the proportion of
states valued as worse than dead (i.e. with a negative value)
and the associated values assigned to these states, which
has resulted in a smaller range for the EQ-5D-5L. One of
the key criticisms of the EQ-5D-3L value set was the
process used to value and subsequently model states worse
than dead, which led to the large range observed [11],
which may not realistically reflect population preferences.
The protocol for the development of the EQ-5D-5L value
set introduced a new method for the valuation of states
worse than dead, which bounded all observed values on a
- 1 to 1 scale [15, 17]. This has reduced the overall pro-
portion of negative values and moved the anchor value of 0
(i.e. the state equivalent to dead). Further work could
compare the characteristics of the health states that have
values close to zero across different value sets.
However, the impact of the change in negative values on
HTA is unclear, as it is not well established how often
states that are worse than dead actually appear in cost-
effectiveness models. There are differences in the propor-
tions of negative states in different conditions, where the
proportion is similar across the EQ-5D-3L and EQ-5D-5L
in Parkinson’s disease, but quite different for multiple
Fig. 6 Bland–Altman plots comparing EQ-5D-3L and EQ-5D-5L, and EQ-5D-5L and crosswalk scores
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sclerosis and COPD, for example. This might be due to
changes in the magnitude of the decrement associated with
the key dimensions for each condition. As the overall range
of EQ-5D-5L values is smaller, the change in QALYs (for
estimates generated from quality of life changes) might be
reduced across the whole scale for states both better and
worse than dead. This depends on the descriptive data,
where respondents could show no change on the 3L (i.e.
‘some’ problems both before and after) whilst showing a
change on the 5L (move from ‘‘moderate’’ to ‘‘slight’’),
leading to higher QALY gains.
It is also useful to compare the scale of the English EQ-
5D-5L value set with those from other countries that were
developed using the same valuation protocol [15]. For
example, the Dutch value set has a minimum value of -
0.446, with around 15% of states valued negatively [33].
The Spanish EQ-5D-5L value set has a minimum value of
- 0.224 [34]. Differences between countries could be due
to cultural differences in preferences as well as the use of
different modelling approaches. Further work should
compare EQ-5D-5L value sets from different countries in
more detail.
It is unclear how the differences between the value sets
indicated in both analysis of the estimates and patient data
will impact the HTA process. This is because the utility
values will be applied to both treatments and their com-
parators, and therefore to some extent the differences may
be even, and the estimates of improvements in quality of
life between arms of a clinical trial could be similar using
the EQ-5D-3L or EQ-5D-5L value sets. The increased
sensitivity of the EQ-5D-5L in terms of the addition of two
extra response levels, and the change possible across the
levels may also favour QALY gains even if the changes in
utility are smaller. An added complexity is whether the
gain is linked to improving quality of life or extending
length of life, and the interaction between the two. This
requires further investigation on clinical trial data, which is
a key part of this programme of research, and has also been
investigated by other researchers, who found different cost-
effectiveness estimates based on the value set used [20].
There are also implications for the NICE reference case
and further decision making based on their recently
released position statement regarding the use of the EQ-
5D-5L. The improvement in the methods used to both
collect and model the valuation data and the increased use
of the improved descriptive system make a strong case for
the use of the new EQ-5D-5L value set. The EQ-5D-3L
value set has benefits if the instrument is still being used in
trials and other settings, but is based on societal prefer-
ences from decades ago. The crosswalk draws on the EQ-
5D-3L values so is prone to the same issues as that value
set. There is also the potential for ‘gaming’ where the
crosswalk may be used instead of the EQ-5D-5L value set
to potentially inflate QALY gains (as the utility range, and
therefore change between states, is larger). One important
point is how to compare results of cost-utility analyses
using the EQ-5D-5L against those using the EQ-5D-3L and
establish the cost per QALY thresholds that should be used.
Further work is required to explore this.
The main limitation of this study is that we have not
tested the impact of the value sets on any clinical trial data,
which would have enabled us to directly compare QALY
estimations. This would allow us to test some of the issues
raised in data previously used for cost-utility analysis, and
is the next planned stage of this programme of research. It
will also be important to compare the psychometric per-
formance, and impact on cost-utility analysis, of the EQ-
5D-5L descriptive system and value set with those of other
widely used generic measures. In particular, comparisons
with version two of the SF-6D (SF-6Dv2) [35], which has
been valued using DCE with duration methods, would be
useful.
5 Conclusions
In conclusion, we have demonstrated key differences in the
theoretical and observed values from three EQ-5D value
sets that can be used in HTA. The value sets will lead to
differences, and the use of the EQ-5D-5L value set will
have implications for the decision-making process carried
out by NICE and may require revision to the guidelines
used for the economic evaluation of health technologies.
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